Navigation Links
Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
Date:1/31/2011

EAST BRUNSWICK, N.J., Jan. 31, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced its intention to offer, subject to market conditions and other factors, $125 million aggregate principal amount of Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission today. Savient also intends to grant the underwriters an option to purchase up to an additional $18.75 million aggregate principal amount of Notes, solely to cover over-allotments. The interest rate, conversion price and other terms of the Notes will be determined by negotiations between Savient and the underwriters.

Savient expects to use the net proceeds of the offering to commercialize KRYSTEXXA™ in the United States, including completion of its ongoing efforts to recruit a sales force, expand its marketing organization and establish a commercial infrastructure, to fund clinical development activities directed to potential label expansion for KRYSTEXXA in the United States, to further develop and seek regulatory approval for KRYSTEXXA in jurisdictions outside the United States, particularly in the European Union, and for general corporate purposes, including working capital.

J. P. Morgan Securities LLC is acting as sole book-running manager of the offering. Lazard Capital Markets LLC is acting as a co-manager of the offering. A copy of the prospectus meeting the requirements of Section 10 of the Securities Act of 1933 may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; Telephone (631) 254-1735.

This press release is neither an offer to sell nor a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy.

Safe Harbor Statement

This press release contains forward-looking statements, including statements about future business prospects, market conditions, KRYSTEXXA, the planned offering and the expected use of proceeds from the offering, that are intended to be covered by the safe harbor provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934. Any statements that are not statements of historical fact (including statements containing the words "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "may," "predict," "will," and "would," and similar expressions) should be considered to be forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated in any forward-looking statements made by Savient, including the factors described in Savient's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, which has been filed with the Securities and Exchange Commission.

SVNT-I


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
(Date:7/27/2017)... Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results ... reported second quarter net sales of $1.954 billion, an ... an increase of 2.1% on a constant currency basis.  ... LDR Holding Corporation acquisition, second quarter 2017 revenues decreased ... on a constant currency basis. ...
(Date:7/26/2017)... , July 26, 2017 E.I. Medical Imaging ... the Bimini SharkLab to custom design the worlds first ultrasound system ... sharks in their native habitat. In preparation for a ... Channel,s Shark Week, Dr. Guttridge approached EIMI with the ... diagnosis directly to hammerhead sharks underwater. ...
Breaking Medicine Technology:
(Date:8/16/2017)... California (PRWEB) , ... August 16, 2017 , ... An August 3rd article ... was the subject of a report in JAMA (the Journal of the American Medical Association). ... 50 were able to achieve BMIs under 30, when compared to patients with lower BMIs. ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data ... today that it was acquired by Advantage Solutions. The Data Council’s IX-ONE ... members include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... opened their doors. They celebrate 30 years in business this year, and they’re ... up-to-date, inviting, tranquil space to serve their patients. , It stands to ...
(Date:8/16/2017)... KS (PRWEB) , ... August 16, 2017 , ... ... latest beneficiary of their recently launched community enrichment program. Partnering once again with ... the KC Superstar competition to help find the area’s very own American Idol. ...
(Date:8/16/2017)... TX (PRWEB) , ... August 16, 2017 , ... ... as a Castle Connolly 2017 Top Doctor. The annual list identifies the nation’s top ... that Dr. Vitenas has made it to the top of Castle Connolly’s coveted ranking. ...
Breaking Medicine News(10 mins):